Latigo Biotherapeutics, Inc. · NASDAQ:LTGO

James B. Tananbaum reported a 14.50% stake in Latigo Biotherapeutics, Inc. (Schedule 13D)

Event Aug 10, 2026 · Filed Aug 17, 2026

James B. Tananbaum reported a 14.50% stake in Latigo Biotherapeutics, Inc., 9,181,328 shares, with active intent on Aug 10, 2026. Filed Aug 17, 2026 (Schedule 13D).

Stake
14.50%
Shares
9,181,328
Intent
Active
What changed
Crossed above 5%
Filed together
7 holders

The filing in full

HolderStakeShares
Foresite Capital Fund VI LP3.50%2,203,800
Foresite Capital Management VI, LLC3.50%2,203,800
Foresite Capital Fund V, L.P.5.60%3,562,984
Foresite Capital Management V, LLC5.60%3,562,984
Foresite Capital Opportunity Fund V, L.P.5.40%3,414,544
Foresite Capital Opportunity Management V, LLC5.40%3,414,544
James B. Tananbaum14.50%9,181,328

Source

View original at SEC

Related